Insulin signaling is distorted in pancreases of Type 2 diabetics

December 13, 2011

SAN ANTONIO (Dec. 13, 2011) -- Insulin signaling is altered in the pancreas, a new study shows for the first time in humans. The errant signals disrupt both the number and quality of beta cells -- the cells that produce insulin.

The finding is described in the journal PLoS ONE. Franco Folli, M.D., Ph.D., of the School of Medicine at The University of Texas Health Science Center San Antonio, and Rohit Kulkarni, M.D., Ph.D., of the Joslin Diabetes Center, Harvard Medical School, Boston, are principal investigators of the study. In a statement, they said: "People knew there was a lack of beta cells because they die off in type 2 diabetes. Here we show the beta cells attempt to replicate, but this is unsuccessful because of the altered signals."

Inability of the beta cells to replicate themselves results in a major defect in insulin secretion during the late stages of type 2 diabetes, said Drs. Folli and Kulkarni.

Insulin is the hormone that lowers blood sugar after a meal. The study, which examined pancreases from cadaveric organ donors, suggests a potential strategy to prevent beta cells from being depleted -- by restoring insulin signals back to normal. This could have important implications for millions of people with type 2 diabetes, a disease marked by poor regulation of blood sugar levels.

Cells in most organs, except the central nervous system, turn over in cell division. One cell dies and another replicates to perform the same function. This is true in the islets of Langerhans, the area of the pancreas where beta cells and other blood glucose regulators originate.

The study also demonstrated, for the first time in humans, that the insulin receptor is critically important for maintaining beta cell mass. This was previously seen in rodent knock-out models of type 2 diabetes mellitus. A receptor is a molecule on the cell's membrane that receives hormones' signals and transmits them into the cell.
-end-
On the Web and Twitter

For current news from the UT Health Science Center San Antonio, please visit our news release website or follow us on Twitter @uthscsa.

About The University of Texas Health Science Center San Antonio

The University of Texas Health Science Center at San Antonio, one of the country's leading health sciences universities, ranks in the top 3 percent of all institutions worldwide receiving federal funding. Research and other sponsored program activity totaled $228 million in fiscal year 2010. The university's schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have produced approximately 26,000 graduates. The $744 million operating budget supports eight campuses in San Antonio, Laredo, Harlingen and Edinburg. For more information on the many ways "We make lives better®," visit www.uthscsa.edu.

University of Texas Health Science Center at San Antonio

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.